INS and type 2 diabetes mellitus: In the BIL phase 3 program, patients who had previously been treated with conventional insulins and were randomized to BIL also had an increase from baseline of TG levels compared to those randomized to IG [LSM difference (BIL-IG), change from baseline to week 26 for type 1 diabetes studies: 20–24 mg/dL; for type 2 diabetes studies: 25–27 mg/dL] [25, 26, 28, 30].